Toboroz
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644· 3. fázis· SystImmune Inc.· Forrás
Contact: Trenis Palmer
Toboroz
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782· 2. fázis· Verastem, Inc.· Forrás
Contact: Matthew Nguyen
Toboroz
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559· 2. fázis· Verastem, Inc.· Forrás
Contact: Trenis Palmer
Toboroz
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738· 1/2. fázis· Orion Corporation, Orion Pharma· Forrás
Contact: David Berz, MD
Toboroz
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT07306559· 1. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298· 1/2. fázis· Pfizer· Forrás
Toboroz
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
NCT07321106· 1. fázis· Cartography Biosciences· Forrás
Contact: Myo Zaw
Toboroz
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432· 1/2. fázis· Vironexis Biotherapeutics Inc.· Forrás
Contact: Myo Zaw
Toboroz
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· 2/3. fázis· Bristol-Myers Squibb· Forrás
Contact: David Berz, Site 0283
Fut, nem toboroz
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066· 1. fázis· SystImmune Inc.· Forrás
Fut, nem toboroz
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453· 1/2. fázis· Pfizer· Forrás
Toboroz
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06533579· 1/2. fázis· Vironexis Biotherapeutics Inc.· Forrás
Contact: Myo Zaw
Toboroz
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242· 1. fázis· SystImmune Inc.· Forrás
Contact: Trenis Palmer, PhD
Toboroz
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
NCT06806033· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522· 2. fázis· Amgen· Forrás
Toboroz
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768· 1/2. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721· 3. fázis· Amgen· Forrás
Toboroz
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808· 1. fázis· Bristol-Myers Squibb· Forrás
Contact: David Berz, Site 0006
Fut, nem toboroz
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222· 2. fázis· BioNTech SE· Forrás
Fut, nem toboroz
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209· 2. fázis· BioNTech SE· Forrás
Toboroz
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357· 1/2. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064· 1/2. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· 3. fázis· Amgen· Forrás
Fut, nem toboroz
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· 3. fázis· BeOne Medicines· Forrás
Fut, nem toboroz
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· 3. fázis· Summit Therapeutics· Forrás
Toboroz
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT06119685· 1/2. fázis· Indapta Therapeutics, INC.· Forrás
Contact: Myo Zaw
Toboroz
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058· 2. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Fut, nem toboroz
Phase III Study of AK112 for NSCLC Patients
NCT06396065· 3. fázis· Summit Therapeutics· Forrás
Fut, nem toboroz
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370· 1/2. fázis· BeiGene· Forrás
Toboroz
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045· 1. fázis· Jazz Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT05032040· 2. fázis· Xencor, Inc.· Forrás
Fut, nem toboroz
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT05238922· 1. fázis· Incyte Corporation· Forrás
Toboroz
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· 3. fázis· BeOne Medicines· Forrás
Toboroz
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
NCT04486833· 1/2. fázis· Genprex, Inc.· Forrás
Contact: Kristi Okino
Toboroz
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804· 1. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766· 1/2. fázis· Inhibrx Biosciences, Inc· Forrás
Contact: Myo Zaw
Toboroz
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933· 1. fázis· Inhibrx Biosciences, Inc· Forrás
Contact: Carla Collier